Announcement: Presentation Options for Authors Unable to Travel to CROI due to Government Travel Restrictions

Themed Discussion Overview

The Program Committee reviews accepted abstracts to identify common themes and selects up to 6 poster abstracts for a 1-hour themed discussion session. A Themed Discussion Leader (discussant) will begin the session with a 4-minute overview of the current state of the field.

Each of the 4 presenters will then deliver a brief 4-minute summary of their poster, highlighting key findings, conclusions, and discussion points.

Following the presentations, the Themed Discussion Leader will guide a discussion with both the presenters and the audience. This discussion will synthesize the key information presented, highlight areas of agreement and controversy, and draw connections to related research in the field.

To close the session, the Themed Discussion Leader will offer a brief summary of the discussion, emphasizing key takeaways and suggesting directions for future research.

See Also: Important Dates | Abstract Submission | Oral Abstract Guidelines | Poster Presentation Guidelines | Registration | Embargo Policy | FAQs

Optional Slide Template: Please note that a title slide that includes your name, institution, and financial disclosures will be provided for you when you submit your final slides in the Speaker Ready Room at CROI. 

Optional Slide Template

Content Slide Guidelines for Presenters

Slide Guidelines
  • A title slide and disclosure will be provided by CROI. These will not count towards the slide limited designated below.
  • Each presenter may use up to 4 slides, excluding the provided title slide.
  • Slides should summarize the research, including key conclusions and future directions.
  • Avoid using overly technical graphs or slides with dense text.
  • Animations (eg, embedded videos or moving elements) are discouraged. If animation is essential, it must be under 30 seconds and verified to function properly when submitting slides in the Speaker Ready Room at CROI.
  • Presenters must share slides in advance with the Themed Discussion Leader.
  • Corporate logos, QR codes, and bar codes are not permitted on slides for oral presentations at CROI.
Slide Format

CROI will support MS PowerPoint or Apple Keynote only. Please ensure that all presentations are in one of these supported formats. High-definition (HD) projectors will be used for all CROI sessions. Please apply widescreen formatting when preparing slides (aspect ratio 16:9; resolution 1920 x 1080).

Slide Submission

Speakers must bring their slides on a portable drive to the Speaker Ready Room and upload slides to the presentation computer 24 hours before the start of the Themed Discussion Session.

Guidelines for Presentation

Use of Trade Names and Promotional Content

Trade names for drugs or products must not be used in presentations. Investigators should refer to drugs, biologics, devices, and other products only by their nonproprietary (generic) names.

Presentations must not include promotional or marketing content. This includes non–science-based promotional language intended to promote or “sell” a product, company, or brand. In addition, presenters may not include QR codes, URLs, or other links that direct attendees to promotional, marketing, or commercial materials.

All content in oral abstract, themed discussion, and poster presentations must remain scientific, objective, and data-focused.

Acknowledgments of Support and Contributors 

Acknowledgments of support may be included in the poster presentation of the abstract at CROI.

Sex Stratification and Other Demographic Variables 

Presentations from randomized trials and cohorts should follow the ICMJE guidelines, including reporting of study designs (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables. For human clinical or epidemiologic studies, the presentation should provide sex-stratified results or identify who was included if it includes only a single population. Presentations of preclinical data including the use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex (as assigned at birth) or gender (where gender is relevant to the study results), this should be identified as a limitation in the study.

See: ICMJE Preparing for Submission

Use of People-First Language and Appropriate Terminology 

See: Appropriate Terminology

Presentations Describing New Compounds 

Please be sure to include information sufficient to allow for meaningful review of compound data; this can include isolation, activity, chemical structure, mechanism of action, toxic effects, and pharmacologic data. The chemical or molecular structure must be shown in the presentation (it need not be part of the abstract or be published in the Abstract eBook).